Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
Virtus KAR Health Sciences A RAGHX
- NAV / 1-Day Return 30.17 / −0.66 %
- Total Assets 143.2 Mil
-
Adj. Expense Ratio
- Expense Ratio 1.390%
- Distribution Fee Level Above Average
- Share Class Type Front Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 75%
USD | NAV as of Jul 04, 2024 | 1-Day Return as of Jul 04, 2024, 12:17 AM GMT+0
Morningstar’s Analysis RAGHX
Will RAGHX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 50.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 11.26 | 17.0 Mil | Healthcare |
AbbVie Inc | 5.04 | 7.6 Mil | Healthcare |
UnitedHealth Group Inc | 4.64 | 7.0 Mil | Healthcare |
The Cooper Companies Inc | 4.60 | 6.9 Mil | Healthcare |
Merck & Co Inc | 4.49 | 6.8 Mil | Healthcare |
IDEXX Laboratories Inc | 4.26 | 6.4 Mil | Healthcare |
Edwards Lifesciences Corp | 4.15 | 6.3 Mil | Healthcare |
West Pharmaceutical Services Inc | 4.02 | 6.1 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 3.77 | 5.7 Mil | Healthcare |
Danaher Corp | 3.76 | 5.7 Mil | Healthcare |